pipette
ESEspañol

Circulating Tumor DNA in Patients with Early-Onset Systemic Sclerosis and Dermatomyositis

C. A. Mecoli, Y. Wang, J. S. Kim, X. Wang, A. Woods, C. Douville, S. D. Curtis, M. Popoli, J. Ptak, L. Dobbyn, N. Silliman, M. B. Smith, L. Fisher, G. Leatherman, L. K. Hummers, L. Christopher-Stine, J. J. Paik, J. Albayda, F. M. Wigley, A. Rosen, L. Casciola-Rosen, C. Bettegowda, N. Papadopoulos, K. W. Kinzler, B. Vogelstein, A. A. Shah

PreprintReal-world use

In the authors' words

Background: Systemic sclerosis (SSc) and dermatomyositis (DM) are autoimmune diseases that have been proposed as models of cancer immunoediting. Autoantibody-defined subsets show divergent cancer risks, yet malignancy often remains clinically occult. We tested whether circulating tumor DNA (ctDNA) can reveal subclinical cancer in new-onset SSc and DM. Methods: We prospectively recruited adults with recent SSc or DM onset. Plasma ctDNA was assessed using a targeted next-generation sequencing panel covering commonly mutated cancer genes. Patients were followed for 18-24 months on average. ctDNA positivity was correlated with subsequent cancer diagnoses. Findings: Among 134 patients (69 SSc, 65 DM), cancer was diagnosed in six (4.5%; three SSc, three DM). ctDNA was detected in four of these six patients (67%) a median of 13 months (range 1.4-17) before clinical diagnosis; in three of four patients, mutations detected in plasma matched those subsequently identified in the same patients primary tumors. ctDNA was also detected in 16 of 128 patients without a cancer diagnosis. ctDNA positivity conferred an 11.4-fold higher risk of malignancy relative to ctDNA negativity and yielded a negative predictive value of 98% and a positive predictive value of 20% for cancer within the observation window. Interpretation: ctDNA testing identified most cancers that emerged within 18 months in new-onset SSc and DM and stratified near-term cancer risk. These findings support larger, interventional trials to determine whether ctDNA-guided surveillance improves timeliness of cancer detection, optimizes imaging and biopsy strategies, and enhances outcomes in patients with SSc and DM.

Main resultLimitation the authors admit

Appeared: Saturday, November 7. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.06.26364657